IPF is a very serious disease with a high unmet medical need for which there are currently no FDA-approved treatments, said study investigator, Luca Richeldi, M.D., Ph.D., Professor of Respiratory Medicine, Chair of Interstitial Lung Disease, University of Southampton, Honorary Consultant Physician, University Hospital Southampton.